Prespective
Moving to the 21^st century, the economical and scientific view of the world has been changed toward the knowledge based economy and cooperation between institutes. CinnaGen as one of the leading company in the region with successful story of the research and development has opened her door for more collaboration.

Extension of our activities with international institutes, technology developments, spin-off-companies in other countries, and opening new market line for CinnaGen brands are our next steps. Starting with Fraunhofer institute, now we have signed agreements with different Research and Development organization in Europe, India and Australia.

In terms of technology development, different areas of biotechnology such as nano-biotech projects for breast cancer, stem cell therapy and more important monoclonal antibodies for therapeutic purposes are our focus for next coming years.

The financial growth rate of CinnaGen has been more than 30% annually from 1999-2005 and more than 300% in 2006. We hope to increase this trend exponentially in future due to scientist’s reliance.

Our goal is to be one of technology owner in the region with extension of collaboration with well known institutes in the world for the next 5 years. In addition, starting manufacturing branches in other countries with proper infrastructure for biotech movement is in the process.

An state-of-the art research and development and manufacturing plant based on the latest CGMP regulation with high quality staff and quality system will guarantee to launch our products to the European countries not latter than 2010.